Background Concomitant treatment with amiodarone and perhsexiline has been considered
to be relatively contraindicated because of the hypothetical risk of potentiated adverse …

Background: Perhexiline, originally used as a first-line prophylactic antianginal agent, is now
regarded primarily as a treatment for otherwise refractory myocardial ischemia. Recent …

We tested the hypothesis that resolution versus persistence of symptomatic ischaemia
and/or development of nausea/dizziness on the third day of loading with perhexiline maleate …

Perhexiline is a prophylactic anti‐anginal agent that ameliorates the metabolic basis for
myocardial ischaemia and is increasingly used in the management of acute coronary …

Objective: To document a case of perhexiline toxicity associated with concurrent treatment
with paroxetine. Clinical Features: An 86‐year‐old woman was admitted to hospital when …

Background: The polymorphic nature of cytochrome P450 2D6 has made therapeutic drug
monitoring of the anti-anginal agent perhexiline a compulsory step in reducing adverse …

Materials and Methods: Two hundred patients at steady-state on long-term perhexiline were
identified retrospectively. The ratio of maintenance dose to steady-state plasma …

Perhexiline is a unique anti-anginal agent that is frequently used in the treatment of chronic
refractory angina. Its utility has been limited because of its complex pharmacokinetics that …

Aims 1) To develop an estimate of oral clearance (/F) for the antianginal agent perhexiline
based on the ratio of cis‐OH‐perhexiline metabolite/parent perhexiline plasma …

Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy
in the management of angina pectoris. However, hepatic and neurological adverse effects …